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Brain-derived neurotrophic factor (BDNF) represents promotesa key molecule for the
survival and differentiation of specific populations of neurons in the central nervous
system. BDNF also regulates plasticity-related processes underlying memory and
learning. A common single nucleotide polymorphism (SNP) rs6265 has been identified on
the coding sequence of human BDNF located at 11p13. The SNP rs6265 is a single base
mutation with an adenine instead of a guanine at position 196 (G196A), resulting in the
amino acid substitution Val66Met. This polymorphism only exists in humans and has been
associated with a plethora of effects ranging from molecular, cellular and brain structural
modifications in association with deficits in social and cognitive functions. To date, the
literature on Val66Met polymorphism describes a complex and often conflicting pattern of
effects. In this review, we attempt to provide a unifying model of the Val66Met effects. We
discuss the clinical evidence of the association between Val66Met and memory deficits,
as well as the molecular mechanisms involved including the reduced transport of BDNF
mRNA to the dendrites as well as the reduced processing and secretion of BDNF protein
through the regulated secretory pathway.
Keywords: neurotrophins, BDNF, memory deficits, post-traumatic stress disorder, hippocampus atrophy, dendritic
mRNA trafficking, regulated protein secretion
BDNF AND ITS Val66Met POLYMORPHISM
The development and plasticity of the nervous system are deeply
influenced by a family of neurotrophic factors called neu-
rotrophins. In mammals, the neurotrophin family consists of
four related proteins: Nerve growth factor (NGF; Levi-Montalcini
and Booker, 1960), Brain-derived neurotrophic factor (BDNF;
Barde et al., 1982), neurotrophin-3 (NT3; Hohn et al., 1990) and
neurotrophin-4 (NT4; Berkemeier et al., 1991). Since its discovery
three decades ago, BDNF has been firmly implicated in the devel-
opment of the nervous system in vertebrates and in the support
of survival and differentiation of specific populations of neurons
in the central nervous system (Bibel and Barde, 2000; Binder and
Scharfman, 2004; Chao et al., 2006). More recently, BDNF has
also emerged in several functions in the adult brain in which
it is involved in the main plasticity-related processes including
memory and learning (Tyler et al., 2002; Yamada et al., 2002).
A common single nucleotide polymorphism (SNP) rs6265 has
been identified on the coding sequence of human BDNF located
at 11p13 (Hall et al., 2003). This single base mutation, present-
ing an adenine instead of a guanine at position 196 (G196A),
results in the amino acid substitution Val66Met (Hall et al., 2003).
The polymorphism Val66Met only exists in humans and has been
associated with a plethora of effects ranging from detrimental
molecular, cellular and brain structural modifications associated
with social and cognitive dysfunction (Dincheva et al., 2012).
While the literature on this polymorphism is rapidly increasing,
there is little consensus on the pattern of results. In this review,
we discuss how this single nucleotide variant affects molecular
mechanisms of memory formation and maintenance and sum-
marize clinical evidence on the association between Val66Met
SNP and memory deficits. In conclusion, we hypothesize a bio-
logical mechanism underlying the memory deficits associated
with the Val66Met polymorphism of BDNF.
CLINICAL ASPECTS OF Val66Met
The first association between the BDNFVal66Met SNP and a clin-
ical phenotype was reported in schizophrenic patients, their rela-
tives and healthy controls (Egan et al., 2003). This study showed a
specific effect on cognitive functions where the Met BDNF allele
reduced the delayed recall of episodic memory in all three groups
but had no influence on other cognitive domains or intelligence
quotient (IQ). Both Egan et al. (2003) and Hariri et al. (2003)
demonstrated that Met BDNF carriers displayed reduced hip-
pocampal engagement during encoding and retrieval of a spatial
task with respect to Val/Val homozygotes. Two independent MRI
investigations (Pezawas et al., 2004; Szeszko et al., 2005) extended
the findings of Egan and Hariri (Egan et al., 2003; Hariri et al.,
2003) by demonstrating in affectively ill individuals that Val/Met
heterozygotes displayed lower hippocampal volumes than their
Val/Val counterparts. In addition, there was volume reduction of
www.frontiersin.org October 2013 | Volume 7 | Article 188 | 1
Baj et al. BDNF mRNA Val66Met-associated memory deficits
the gray matter in the dorsolateral prefrontal cortex (DLPFC),
which is implicated in learning and memory processes involv-
ing also the hippocampus (Pezawas et al., 2004; Hwang et al.,
2006; Benjamin et al., 2010). Further, in a community of elderly
Caucasian individuals, BDNF Val/Val homozygotes performed
significantly better compared to both Val/Met heterozygous and
Met/Met homozygous individuals on a delayed recall task and
an alphabet-coding task (ACT), a measure of processing speed.
Another study also noted a decrease in hippocampal volume in
Met BDNF allele carries, although it did not reach statistical sig-
nificance (Goldberg et al., 2008) while other authors confirmed
the hippocampal volume reduction (Benjamin et al., 2010; Teh
et al., 2012; Tost et al., 2013).
In a fascinating study, Schofield et al. (2009) found a sig-
nificant increase in hippocampal activity in Met BDNF carriers
compared to BDNF Val/Val homozygotes during the auditory
oddball task. The auditory oddball task has been asserted to
measure auditory attention and auditory capacity. It is a task
in which the subject must detect a relevant (“oddball”) stim-
ulus, which is presented infrequently and randomly within a
train of task-irrelevant stimuli. Schofield and colleagues argued
that Met BDNF carriers might require greater hippocampal acti-
vation than their BDNF Val/Val counterparts to process audi-
tory stimuli presented during the task, inadvertently deplet-
ing resources for prefrontal processing of stimuli. Similar cir-
cuit dysregulation has been observed previously. A protective
role for the Met allele has also been proposed for enhanced
verbal reasoning in the elderly (Harris et al., 2006), systemic
lupus erythematosus (Oroszi et al., 2006), multiple sclero-
sis patients (Zivadinov et al., 2007; Cerasa et al., 2010), and
Parkinson’s disease (Foltynie et al., 2005), although others have
challenged these findings (Liguori et al., 2007; Miyajima et al.,
2008).
Additional studies found either a gender-specific association
(Echeverria et al., 2005) or no association in schizophrenic and
bipolar patients (Strauss et al., 2004; Tramontina et al., 2009)
as well as in other clinical conditions characterized by cogni-
tive impairment such as multiple sclerosis (Cerasa et al., 2010),
HIV-associated neurocognitive disorders (Levine et al., 2012)
and Parkinson’s disease (Guerini et al., 2009). The disagree-
ment between results could be due to a number of differences
in study design (Hong et al., 2011). First, these studies are typi-
cally characterized by relatively small sample size. Second, there
is a noticeable variability in the phenotypes analyzed in these
researches. Specifically, it is striking how many different tasks
have been used in the field to assess arguably similar (or the
same) cognitive functions. In animal studies, BDNF is stud-
ied especially in the hippocampus and therefore, the impact
of the Val66Met polymorphism could have been more evi-
dent in studies focused on hippocampus-specific tasks. More
orchestrated approaches to behavioral phenotyping for cog-
nition in the design of genetic and allelic association stud-
ies on BDNF are highly needed and are likely to be fruit-
ful. Otherwise, using the mere Mini Mental State Examination
(MMSE), the effects of BDNF Val66Met polymorphism on cog-
nition may not emerge (Zivadinov et al., 2007; Forlenza et al.,
2010).
More recently, Mandelman and Grigorenko (2012) conducted
a meta-analysis examining the relationship between BDNF
Val66Met and cognition, but did not find significant associations
between the Val66Met polymorphism and any of the phenotypes
that were included. The obvious additional candidates for sources
of such between-study heterogeneity are demographic character-
istics such as gender, age and phase of illness, ethnicity, physical
exercise, cardio-vascular health status and diagnosis (Verhagen
et al., 2010; Lu et al., 2012; Martinho et al., 2012; Nagata et al.,
2012; Smith et al., 2012). Furthermore, it is possible that the
genetic variant may be associated with some intermediate pheno-
types, which, in turn, could be related to some but not all of the
cognitive phenotypes examined. Given the multitude of BDNF
protein isoforms and the diversity of its transcripts in different
brain areas, it is conceivable that cognitive phenotypes should be
grouped not by their behavioral similarities, but by similarities in
the brain activation pathways that underlie these phenotypes.
BIOLOGICAL ASPECTS OF THE Val66Met MUTATION
It is important to highlight that the vast majority of the results
reported in the literature and summarized here, were obtained
by investigations on homozygous BDNF Met/Met (Met BDNF)
mice while the double mutated Met/Met allele is quite rare
in humans. Indeed, data from human population are collected
mostly from individuals with BDNF Val/Met (single allele muta-
tion) or BDNF Val/Val (Mandelman and Grigorenko, 2012). The
biological effects of the SNP rs6265 in the BDNF coding sequence
have been studied using several different model systems, starting
from cell culture, to animal models or in correlation with dis-
eases affecting the human population. In their initial work, using
an in vitro neuronal culture system, Egan and coworkers (Egan
et al., 2003) demonstrated that Met BDNF in fusion with GFP
and transfected in neurons is produced at levels similar to the
control Val BDNF-GFP. The knock-in animal model for the Met
BDNF allele created by Chen et al. (2006; Dincheva et al., 2012)
confirmed that the total BDNF production is not affected by the
polymorphism. A recent detailed analysis of BDNF protein in spe-
cific brain areas of BDNF Val and Met knock-in mice showed
slight but significant reduction of BDNF in the hippocampus
(HPC) and in prefrontal (PFC) cortex while no variations were
found at the level of amygdala and striatum (Bath et al., 2012; Yu
et al., 2012).
Chen and coworkers were first to describe the functional
importance of the Met BDNF allele in the brain. They reported
alterations in hippocampal anatomy of the Met BDNF knock-
in model. The total hippocampal volume of Met BDNF mice
was found to be reduced and dentate gyrus (DG) neurons were
measured as significantly smaller in total volume and dendritic
complexity while the soma size was not affected (Chen et al.,
2008). Similar neuronal volumetric reduction was reported also
on ventromedial prefrontal cortex cells, while neurons from the
striatum were not affected (Yu et al., 2009). The same mouse
model was used to establish the effect of Met polymorphism in
prefrontal cortex (PFC) where a specific atrophy of apical den-
drites of layer 5 pyramidal cells was found (Liu et al., 2012).
Furthermore, the induction of synaptogenesis in PFC by ketamine
administration on brain slices was almost abolished indicating
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impaired synaptic formation/maturation. Met BDNF mice pre-
sented alterations in the generation of LTP at the CA3-CA1
synapse. Ninan and colleagues were able to dissect out the mech-
anism of this deficit revealing that NMDA receptor-dependent
LTP was specifically affected while the non-NMDA receptor neu-
rotransmission (i.e., mGluR) was normal (Ninan et al., 2010;
Pattwell et al., 2012). Yet, it remains unclear if these BDNF effects
on the NMDA receptor are either due to a deficit in the basal
regulation of the NMDA receptor trafficking and expression or
to an altered acute activity-dependent release of BDNF, in Met
BDNF mice. Additional evidence of deficits in neuronal activa-
tion was observed in ventromedial prefrontal cortex ofMet BDNF
mice following fear extinction tests: theMet substitution results in
reduced cellular activation (–50%), visualized by cFOS positivitity
(Yu et al., 2009).
EFFECTS OF Val66Met ON BDNF SECRETION AND
TRAFFICKING
Apart from of the evidence of a normal (total brain) or reduced
(HPC and PFC) production of BDNF in presence of the Val66Met
mutation, several studies reported a differential subcellular dis-
tribution of BDNF upon Met substitution. BDNF was shown to
regulate synaptic strength in a site-restricted manner and there-
fore, its subcellular distribution is very important for the func-
tional role of this neurotrophin (Steward and Schuman, 2001;
Horch and Katz, 2002; Lu, 2003; Alonso et al., 2004; Horch, 2004).
Given the morphological structure of neurons, highly polarized
cells with a relatively small soma and long dendritic/axonal pro-
cesses, the BDNF protein must overcome several challenges to
exert its functions correctly. In particular, just like many other
synaptic proteins, BDNF is synthesized in response to synaptic
stimuli and needs to be delivered at synapses located in specific
subcellular districts where it can modify their structure and func-
tion (Tongiorgi, 2008; Edelmann et al., 2013). Jiang and Schuman
reviewed the three different models that explain how a pro-
tein can be selectively delivered at activated synapses (Jiang and
Schuman, 2002). In one model, the protein is synthesized in the
soma and becomes tagged for a specific group of synapses, where
it is subsequently transported. The second model describes the
protein as being transported to dendrites without a specific tar-
get but is then captured by “tagged” synapses which have been
appropriately stimulated. In the third model, which is in con-
trast with the previous two, it is the mRNA that is transported
to dendrites and where it is locally translated by the protein
synthesis machinery localized in proximity to synapses. Most
researchers in the field agree that these three mechanisms might
coexist within the same cell and may even regulate the very same
protein.
BDNF represents one clear example of coexistence of multi-
ple mechanisms for dendritic trafficking. The mRNAs encoding
for BDNF were found to be transported and actively accumu-
late along dendrites following stimulation of electrical activity
(Tongiorgi et al., 1997, 2004; Jakawich et al., 2010; Baj et al.,
2013). BDNF was also shown to be transported to dendrites
in large, dense-core secretory vesicles (Edelmann et al., 2013).
Accordingly, recent studies have investigated the possible impact
of the Met polymorphism on these BDNF sorting mechanisms.
In neurons, Met BDNF seems to be preferentially produced
and accumulated within the somatic district and only partially
transported in the proximal area of the primary dendrites whereas
Val BDNF is produced and transported also in secondary and
tertiary dendrites (Egan et al., 2003; Chen et al., 2004, 2006).
The abnormal distribution of Met BDNF in cell body and den-
drites of hippocampal neurons appears to be accompanied by
a significant reduction in the secretion of this neurotrophin. In
particular, secretion of BDNF induced in response to electrical
stimuli is compromised (30% decrease) while the constitutive
secretion of BDNF is not affected (Egan et al., 2003; Chen
et al., 2004, 2006). BDNF sorting into the regulated secretory
pathway appears to be mediated by two mechanisms. The first,
involves interaction of the sorting receptor carboxypeptidase-E
(CPE) with a tetrad of aminoacids (I16, E18, I105, D106) in
the mature BDNF region forming a specific recognition motif,
which is not affected by the Val66Met mutation (Lou et al., 2005).
The second sorting mechanism, regards the interaction of sor-
tilin with the pro-BDNF region comprised between aminoacid 44
and 102, wherein the Val66Met occurs (Chen et al., 2005). The
current view is that substitution of the Val66 with a Met causes
less efficient interaction with sortilin and therefore Met BDNF
proteins show decreased targeting to the regulated secretory path-
way (Dincheva et al., 2012). Further evidence in support of this
hypothesis was provided by experiments in which Met BDNF
was able to impair the trafficking of BDNF Val following for-
mation of BDNF Val and Met BDNF heterodimers (Chen et al.,
2004).
The combinatorial effect of normal BDNF production but
decreased dendritic localization and secretion is correlated with
the reduction of BDNF in SecII-positive secretory vesicles and
Synaptophysin-positive synapses (Egan et al., 2003). The dif-
ferent biochemical pathways involved in the production and
sorting of BDNF was also specified by Del Toro et al. (2006),
who not only confirmed the reduction of Met BDNF in SecII
vesicles but also found an accumulation of Met BDNF in Giantin-
positive Golgi vesicle. Moreover, they found no visible differences
between Val BDNF and Met BDNF in calnexin-positive vesi-
cles while the total number of vesicles containing BDNF was
strongly reduced by about 30% (Del Toro et al., 2006). It is
important to note that the polymorphism at position 66 in
the BDNF pro-domain does not affect the cleavage of the pro-
BDNF form and the generation of the mature form of BDNF
(Chen et al., 2004).
Transport dynamics of Met BDNF and Val BDNF through
the secretory pathway are comparable. Indeed, the calculation
of the mean translocation velocity of secretory vesicles in den-
drites showed no differences between the two alleles (Del Toro
et al., 2006), suggesting that the transported BDNF protein
may probably account for the constitutive secretion of this neu-
rotrophin which is also not affected by the Val66Met polymor-
phism. However, the physiological role of BDNF is only partially
supported by this basal BDNF secretion. In fact, Bath et al. (2008)
showed that TrkB activation in neurogenic regions, revealed
by the intensity of pTrkB staining on total TrkB (in SVZ and
OB), was reduced by 30% in Met BDNF brains. These data
point out that activity-dependent BDNF secretion is required
www.frontiersin.org October 2013 | Volume 7 | Article 188 | 3
Baj et al. BDNF mRNA Val66Met-associated memory deficits
for a physiological activation of TrkB to sustain neurogenesis
and neuroblast survival. Accordingly, a recent characterization
of the neurogenesis at the level of the DG in Met BDNF mice,
calculated as density of BrdU positive cells, found a consider-
able reduction (ca. –25%) of proliferating neural progenitors
(Bath et al., 2012).
EFFECTS OF BDNF Val66Met: AN mRNA PERSPECTIVE
Among the studies that report a reduced amount of dendritic
BDNF protein in presence of the Val66Met polymorphism, one
study compared the trafficking of BDNF mRNA with the wild
type sequence (Val allele: G196) or with the mutation (Met allele:
A196). The results revealed significantly reduced dendritic traf-
ficking of BDNF mRNA bearing the A196 mutation (Chiaruttini
et al., 2009). This effect was found to be due to a reduced affinity
of the RNA-binding protein Translin for the mutated allele. The
RNA-binding domain of Translin contains a pocket made by three
aminoacids (His90, Arg21, Glu89), which specifically recognizes
a guanosine by forming three hydrogen bonds (Figures 1A,C).
The transition from Guanine to Adenine at position 196 reduces
the number of possible hydrogen bonds to just one, with a dra-
matic reduction in binding stability of Translin to the mutated
BDNF mRNA (Figure 1B). Since the minimal tertiary configu-
ration with which Translin can bind to an mRNA is a dimer,
the authors hypothesized that there could be a second Guanine
on BDNF mRNA that binds to the other Translin participat-
ing to the dimer (Figure 1D). Indeed, a second Guanine was
identified at position 177 and when mutated to an Adenine, it
abolished the Translin-mediated trafficking in dendrites exactly
like the Guanine at position 196 (Chiaruttini et al., 2009). This
mutation of Guanine at position 179 has no effect. Translin is
involved in the trafficking of other transcripts associated with
synaptic functions such as the mRNA encoding for CamK-II
and the small non-coding RNA BC-1, implicated in regulat-
ing protein translation in dendrites (Li et al., 2008; Jaendling
and McFarlane, 2010). In addition, Translin can associate with
a similar protein called TRAX to form a complex known as
C3PO, which is highly conserved from fungi to humans (Tian
et al., 2011; Ye et al., 2011). This complex is a component of
the RISC complex and is required for the mechanisms of RNA
interference, which regulates mRNA stability and translation at
synapses. Remarkably, Translin KO-mice have several behavioral
abnormalities (Li et al., 2008; Jaendling and McFarlane, 2010).
Thus, abnormal interactions of an mRNA with Translin may
have profound effects on its trafficking, stability and translation
(Wu et al., 2011).
A recent study in humans found a strong correlation, defined
by linkage disequilibrium, among rs6265 and two other SNPs
in the 3′UTR of BDNF (rs11030100 and rs11030099). All these
SNPs transform BDNFmRNA into a target for themiR-26s family
providing a supplementary component involved in regulation of
mRNA stability and translation (Caputo et al., 2011). These pieces
of evidence are consistent with findings in BDNF Met/Met mice
and suggest that the reduced availability of BDNF mRNA in den-
drites of Met BDNF neurons leads to a deficiency of local protein
translation and may contribute to deficits in activity-dependent
release of Met BDNF from post-synaptic terminals.
FIGURE 1 | Interaction between translin and human BDNF mRNA is
hampered by the mutation G196A. (A) Translin amino acids His-90,
Arg-21, Glu-89 form three hydrogen bonds with G196 (normal human
BDNF) but only one with A196 (mutated BDNF, in B). (C) The nucleotide:
amino acid selectivity for each of the four binding sites on translin. (D)
Three-dimensional modeling of translin dimer binding to human BDNF
mRNA.
TOWARD A UNIFIED BIOLOGICAL HYPOTHESIS FOR THE
Val66Met DEFICIT
At the current state of research, a number of studies support the
view that the BDNF Val66Met polymorphism, with one or two
copies of the Met BDNF allele, can lead to altered performance of
learning and memory functions, especially with impairments in
hippocampal and cortical processes, suggestive of reduced neuro-
plasticity. To better understand how a small change in the BDNF
sequence may determine so many effects, we believe that it is
worth trying to assemble the large body of data available in the
literature into a unified model at the cellular, anatomical, and
behavioral level.
From a cellular standpoint, converging studies suggest that
neuroplasticity deficits can be accounted mainly by impairment
of activity-dependent translation and release of the Met BDNF
from post-synaptic sites. We now describe how this deficit can
result from a combination of reduced transport of Met BDNF
mRNA in dendrites and an altered processing of the mutated
protein through the regulated secretory pathway.
The deficit in mRNA trafficking found in BDNF bearing
the Met allele (G196A at mRNA level), can be put into the
broader perspective of the so called “spatial code model of BDNF
transcripts” (Chiaruttini et al., 2008; Tongiorgi, 2008). BDNF
is encoded by multiple mRNAs generated by alternative splic-
ing. Eleven non-coding 5′UTR exons are alternatively spliced
to a common downstream exon containing the coding region
and a 3′UTR with two polyadenylation signals (An et al., 2008)
which produce 11 different transcripts in rodents and 14 in
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humans, each with two 3′ tails (Aid et al., 2007; Pruunsild et al.,
2007). Following a series of studies demonstrating the differ-
ential subcellular distribution of the different BDNF transcripts
(Pattabiraman et al., 2005; Chiaruttini et al., 2008), a hypoth-
esis was put forward that the multiple transcripts encoding the
very same protein are used to generate a spatial code for express-
ing BDNF at restricted subcellular locations, leading to localized
effects (Tongiorgi, 2008). This model was recently completed
by real-time PCR analysis of all rodent transcripts in vivo (Baj
et al., 2013). In untreated rats, various BDNF transcripts were
detected in dendritic fields of the hippocampus (exons 6 and 7
in CA1; exons 1, 6, and 9a in CA3; and exons 5, 6, 7, and 8 in
DG). However, due to the very low levels of most of these tran-
scripts, the exon 6 was found to be the main transcript present
in dendrites at resting conditions. Strong neuronal activation by
pilocarpine-induced status epilepticus caused an increase in all
hippocampal dendritic laminae of BDNF transcripts encoding
exons 2, 4, and 6 and also of BDNF exons 3 and 9a in DG molec-
ular layer, whereas the other transcripts were restricted to the
soma (Baj et al., 2013). Importantly, overexpression or silenc-
ing of the four most abundant brain BDNF transcripts, encoding
exon 1, 2, 4, or 6, led to differential effects on dendritic mor-
phology in vitro, with exons 1 and 4 affecting only the proximal
dendritic domains and exon 2 and 6 being able to shape the
distal dendritic district (Baj et al., 2011). This differential effect
was demonstrated to be due to localized expression of BDNF
and activation of TrkB receptor in the same subcellular domains
where the specific mRNAs are localized (Baj et al., 2011). The
conversion of the G196 to A196 impairs the transport of BDNF
mRNA into dendritic domains (Chiaruttini et al., 2009), and
therefore, the mutated BDNF mRNAs can only be translated in
the soma. Since the change G196A is located within the coding
region, it is present in all BDNF mRNA variants but its effects
on mRNA trafficking are only evident for those BDNF transcripts
that are actively transported to dendrites (such as exon 2 or 6).
However, activity-dependent secretion is also impaired, causing
entrapment of the Met BDNF protein within the Golgi appara-
tus and the observed increase in the soma and depletion from
distal dendrites (Egan et al., 2003; Chen et al., 2004) (Figure 2).
In this model, the converging misplacement of BDNF mRNA
and protein can affect the ability of BDNF to maintain dendritic
branching in the periphery of the neuron and support plasticity
at synapses in distal dendrites which represent, notably, the large
majority of glutamatergic excitatory synapses (Figures 2 A,B).
Anatomically and physiologically, the available findings are
consistent with morphological and functional hippocampal atro-
phy and subsequent cortico-cortical disconnection syndrome,
which involves the disruption of neural networks between the
anterior and posterior cerebral areas (Delbeuck et al., 2003;
Nagata et al., 2010). Met carriers, rather than subjects with the
Val/Val phenotype, may benefit from a protective role on execu-
tive function through hippocampus cortical atrophy or other sub-
cortical tract changes, as reported in previous studies on elderly
people. This observation may in part, explain the reason why this
polymorphism despite its deleterious effects remains highly dif-
fused in the world population. Interestingly, as pointed out by
Li et al. (2010), the negative effects of the BDNF polymorphism
FIGURE 2 | Model of the biological effects of Val and Met BDNF alleles
in the hippocampus. (A) In Val/Val neurons, the four most abundant brain
BDNF transcripts, encoding exon 1, 2, 4, or 6, are differentially localized in
dendrites, forming a gradient with exon 1 being restricted to the soma and
exons 2, 4, and 6 in dendrites at increasing distances according to the
gradient 4<2<6. Exons 1 and 4 can affect only the morphology of proximal
dendrites while exon 2 and 6 are able to shape the distal dendrites. (B) In
Met/Met neurons, transport of BDNF mRNA in distal dendritic districts is
impaired and all BDNF mRNA isoforms accumulate in the cell soma. Met
BDNF protein increases in the soma, also due to poor secretion. It is
unclear if axonal transport and secretion can be affected by the Met
mutation. (C) BDNF released from DG granule cells is shown in red, while
BDNF released from CA3 neurons is shown in blue. (1.BDNF) Secretion of
Met BDNF from the soma of DG granule cells is altered and provides
insufficient local trophic support for survival and differentiation of DG
subgranular neural stem cells. (2.BDNF) Release of Met BDNF from
dendrites of DG neurons is affected and cannot provide sufficient autocrine
support to dendrites which show reduced arborization. (3.BDNF) Local
production and release of Met BDNF from apical dendrites of CA3 neurons
is reduced and cannot provide the target-derived trophic support to promote
innervation of CA3 from newly formed mossy fibers and autocrine support
to CA3 dendrites. (4.BDNF) It is unknown if anterogradely transported Met
BDNF in mossy fibers can support dendrites from CA3 neurons and if
anterograde transport of BDNF is affected by the Met mutation.
on episodic memory are most likely observed when associative
and executive demands are high. These observations are in line
with the hypothesis that the magnitude of genetic effects on cog-
nition is greater when brain resources are reduced, as with old
age. Accordingly, the logical consequence of the strong effects of
Met BDNF allele on mental performance are pronounced in the
elderly, with poor or no impact on reproduction and therefore,
transmission of the allele to the following generations can
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be ensured thus contributing to the maintenance of this mutation
through the population. In addition, carriers of the Met allele
are more likely to develop post-traumatic stress disorder after
traumatic experiences.
In Figure 2C we summarize how deficits in Met BDNF secre-
tion and transport, observed at the cellular level, may affect
the hippocampal neuronal circuit. According to this model,
since various studies reported that survival and differentia-
tion of DG subgranular neural stem cells are reduced, secre-
tion of Met BDNF from the soma of DG granule cells is
altered and provides insufficient local trophic support (Figure 2).
In addition, since DG dendrites were shown to have reduced
arborization, the model predicts that release of Met BDNF
from dendrites of DG neurons is affected and cannot pro-
vide sufficient autocrine support. Following stressful situations,
Met/Met individuals may undergo more easily to atrophy of
apical dendrites of CA3 neurons. According to our model, the
local production and release of Met BDNF from apical den-
drites of CA3 neurons is reduced and thus cannot provide
target-derived trophic support to promote the innervation of
CA3 from newly formed mossy fibers and autocrine support to
CA3 dendrites. It is currently unclear if Met BDNF present in
mossy fibers can support dendrites from CA3 neurons and if
anterograde transport of BDNF is affected by the Met muta-
tion. One plausible hypothesis is that BDNF released from mossy
fiber axons may stimulate dendritic targeting of BDNF mRNA
in CA3 apical dendrites, thus contributing to a local autocrine
loop which supports the maintenance of apical dendritic
arborization.
In conclusion, the view proposed here does not claim to be
the ultimate interpretation of the available data but intends to
be a stimulus for the scientific community to develop a con-
sensus model on the biological mechanisms of one of the most
fascinating human mutations affecting cellular functions, brain
morphology, and cognition.
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